Relmada Therapeutics, Inc. financial data

Symbol
RLMD on Nasdaq
Location
2222 Ponce De Leon Blvd. 3 Rd Floor, Coral Gables, FL
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 423 % -42.1%
Debt-to-equity 31.3 %
Return On Assets -205 % -83.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 73.3M shares +143%
Common Stock, Shares, Outstanding 33.2M shares +10%
Entity Public Float 89M USD +22%
Common Stock, Value, Issued 33.2K USD +10%
Weighted Average Number of Shares Outstanding, Basic 33.2M shares +10%
Weighted Average Number of Shares Outstanding, Diluted 33.2M shares +10%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 29.8M USD -40.3%
General and Administrative Expense 28M USD -32.8%
Operating Income (Loss) -57.8M USD +36.9%
Nonoperating Income (Expense) 1.67M USD -67.7%
Net Income (Loss) Attributable to Parent -56.2M USD +35%
Earnings Per Share, Basic -1 USD/shares +37.3%
Earnings Per Share, Diluted -1 USD/shares +37.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.38M USD -6.69%
Assets, Current 14.9M USD -73.3%
Other Assets, Noncurrent 22K USD 0%
Assets 14.9M USD -73.3%
Accounts Payable, Current 1.45M USD -38%
Accrued Liabilities, Current 3.74M USD -34.9%
Liabilities, Current 5.19M USD -35.8%
Liabilities 5.41M USD -33.2%
Retained Earnings (Accumulated Deficit) -678M USD -9.03%
Stockholders' Equity Attributable to Parent 9.47M USD -80.1%
Liabilities and Equity 14.9M USD -73.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.1M USD -38.6%
Net Cash Provided by (Used in) Financing Activities 222K USD
Net Cash Provided by (Used in) Investing Activities 15.4M USD +52.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 33.2M shares +10%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 23.5M USD +4686%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.38M USD -6.69%
Deferred Tax Assets, Valuation Allowance 115M USD +4.74%
Preferred Stock, Shares Authorized 200M shares
Additional Paid in Capital 688M USD +2.69%
Share-based Payment Arrangement, Expense 4.48M USD -46%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares